NCT Number: NCT02861573
Phase: Phase 1|Phase 2
Trial Summary: The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer ( – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Merck Sharp & Dohme LLC
Acronym:
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives